

### REMARKS

The proposed claims are substantially identical to those that have been granted in the European counterpart, issued as European patent 1432402 B1. Multiple dependencies have been eliminated, and the medical use claims have been replaced by method of treatment claims. The claim (30) that specifies delivery vehicles has been limited to the preferred embodiment.

No additional Information Disclosure Statement is included as all of the documents of which applicants are aware have already been cited in IDS submissions.

Applicants respectfully request that full faith and credit be accorded the European examination and its outcome.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket No. 532552000102.

Respectfully submitted,

Dated: November 23, 2009

By: \_\_\_\_\_ / Kate H. Murashige /  
 Kate H. Murashige  
 Registration No.: 29,959  
 MORRISON & FOERSTER LLP  
 12531 High Bluff Drive, Suite 100  
 San Diego, California 92130-2040  
 Telephone: (858) 720-5112  
 Facsimile: (858) 720-5125